$1.75
1.16% today
Nasdaq, Aug 12, 04:45 pm CET
ISIN
US14757U1097
Symbol
CASI

CASI Pharmaceuticals Inc Stock price

$1.73
+0.33 23.57% 1M
-0.69 28.51% 6M
-1.10 38.87% YTD
-4.77 73.38% 1Y
-2.17 55.64% 3Y
-17.67 91.08% 5Y
-13.07 88.31% 10Y
-282.07 99.39% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.10 6.14%
ISIN
US14757U1097
Symbol
CASI
Industry

Key metrics

Basic
Market capitalization
$26.8m
Enterprise Value
$32.6m
Net debt
$5.8m
Cash
$12.7m
Shares outstanding
15.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.9 | 2.1
EV/Sales
1.0 | 2.6
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
3.5%
Return on Equity
-2,120.9%
ROCE
-568.8%
ROIC
-
Debt/Equity
-2.3
Financials (TTM | estimate)
Revenue
$31.4m | $12.8m
EBITDA
- | -
EBIT
$-40.4m | $-33.6m
Net Income
$-40.5m | $-32.7m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
8.4% | -55.3%
EBITDA
- | -
EBIT
-38.3% | 2.3%
Net Income
-32.8% | 16.7%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
56.6%
EBITDA
- | -
EBIT
-128.9%
Net
-129.1% | -256.5%
Free Cash Flow
-
More
EPS
$-2.6
FCF per Share
-
Short interest
0.2%
Employees
233
Rev per Employee
$120.0k
Show more

Is CASI Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

CASI Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CASI Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a CASI Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from CASI Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
8% 8%
100%
- Direct Costs 14 14
13% 13%
43%
18 18
5% 5%
57%
- Selling and Administrative Expenses 45 45
10% 10%
143%
- Research and Development Expense 8.38 8.38
14% 14%
27%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -40 -40
38% 38%
-129%
Net Profit -40 -40
33% 33%
-129%

In millions USD.

Don't miss a Thing! We will send you all news about CASI Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CASI Pharmaceuticals Inc Stock News

Neutral
Accesswire
8 days ago
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is a leading cause of kidney transplant loss, leading to dialysis and/or repeat renal transplant SAN FRANCISCO, CA / ACCESS Newswire / August 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clin...
Neutral
Accesswire
22 days ago
-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition -- CID-103 is a potential best in class, ...
Neutral
Accesswire
3 months ago
BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it will host a live conference call and webcast at 8:00 a.m. PT/11:00 a.m.
More CASI Pharmaceuticals Inc News

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Head office United States
CEO Wei He
Employees 233
Founded 1991
Website www.casipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today